Comparing two treatments for colorectal liver metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of irreversible electroporation (IRE) versus stereotactic body radiotherapy (SBRT) in patients with perivascular or peribiliary colorectal liver metastases that cannot be surgically removed or treated with thermal ablation. The study will assess local control of the tumors over a two-year period, along with overall survival, safety, and cost-effectiveness. Participants will be randomly assigned to receive either IRE or SBRT, both of which are non-thermal treatment options designed to target challenging liver tumors near vital structures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histological documentation of primary colorectal tumor is available;
* 1-3 CRLM visible on ceCT and/or MRI, size 0-5 cm and not eligible for resection or thermal ablation due to location close to a vessel or bile duct;
* Additional CRLM are allowed if considered either resectable or ablatable with a maximum of 10 CRLM. In patients with extrahepatic disease, a maximum of 5 additional CRLM is allowed;
* No or limited extrahepatic disease (1 extrahepatic lesion is allowed, with some exclusions mentioned in the exclusion criteria);
* Prior focal liver treatment is allowed;
* Subjects should preferably be treated with neo-adjuvant systemic therapy;
* Subjects with recurrent (either local or distant-hepatic) CRLM after previous focal treatment who are unsuitable for (further) systemic therapy (further downsizing or conversion to resectable disease improbable);
* Adequate bone marrow, liver and renal function as assessed by laboratory requirements to be conducted within 7 days prior to definite inclusion;
* ASA classification 0 - 3;
* Age \>18 years;
* Written informed consent;

Exclusion Criteria:

* Radical treatment unfeasible or unsafe (e.g. insufficient FLR);
* \>10 CRLM; \>5 CRLM when extra-hepatic disease is present;
* Positive para-aortal lymph nodes, celiac lymph nodes, adrenal metastases, pleural carcinomatosis or peritoneal carcinomatosis;
* Subjects who have progressive disease after neo-adjuvant systemic therapy;
* History of epilepsy;
* History of cardiac disease:
* Uncontrolled hypertension. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen;
* Compromised liver function (e.g. signs of portal hypertension, INR \> 1,5 without use of anticoagulants, ascites);
* Pregnant or breast-feeding subjects;
* Immunotherapy ≤ 2 weeks prior to the procedure;
* Chemotherapy and/or targeted therapy ≤ 2 weeks prior to the procedure;
* Severe allergy to contrast media not controlled with premedication;
* Any condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study.

Where it's running

• Amsterdam UMC - location VUmc
  Amsterdam, North Holland, Netherlands Recruiting

Study contacts

• Principal investigator: Martijn R. Meijerink, Prof. — Amsterdam UMC
• Study coordinator: Danielle J. Vos, M.D.
• Email: interventieradiologie@vumc.nl
• Phone: +3120-4444571

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating a new immuno-adjuvant for colorectal liver metastases after ablation treatments

  This study is testing a new treatment called IP-001 to see if it can boost the immune response and help people with colorectal liver metastases feel better after they have undergone ablation therapies.

  Recruiting Phase 1/2 Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06630624

• Comparing simultaneous and staged surgery for colorectal cancer with liver metastases

  This study is testing whether doing surgery for colon cancer and liver tumors at the same time or in separate stages is better for patients in terms of recovery and overall health.

  Recruiting Oslo University Hospital · Oslo · NCT06200831

• Neoadjuvant therapy followed by local treatment for recurrent colorectal liver metastases

  This study is testing if giving a new treatment before local therapy can help people with recurrent colorectal liver cancer live longer compared to getting local therapy right away.

  Recruiting Phase 3 Amsterdam UMC, location VUmc · Amsterdam · NCT05861505

• Prospective look at liver metastases imaging and tissue patterns in colorectal and breast cancer

  This observational study tests whether 3D maps of histopathological growth patterns in liver metastases align with imaging features from MRI/CT in patients undergoing liver surgery.

  Recruiting Cancer Research Antwerp · Wilrijk, Antwerp · NCT07781306

• Histotripsy plus chemotherapy versus chemotherapy alone for colorectal cancer spread to the liver

  This trial will test whether adding noninvasive histotripsy to standard chemotherapy helps people with unresectable, liver‑confined colorectal cancer metastases stay free of disease progression longer.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07044362

• Combining radiation therapy and PD-1 antibody for liver metastases from colorectal cancer

  This study is testing if combining a special type of radiation therapy with a new immune treatment can help people with liver cancer from colorectal cancer feel better and live longer.

  Recruiting Phase 3 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT06794086

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.